Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund decreased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 99.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 28,478 shares of the company’s stock after selling 4,552,174 shares during the quarter. New York State Common Retirement Fund owned 0.06% of Omnicell worth $1,072,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Covestor Ltd grew its position in Omnicell by 65.6% in the 3rd quarter. Covestor Ltd now owns 1,355 shares of the company’s stock valued at $61,000 after buying an additional 537 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Omnicell in the third quarter valued at approximately $62,000. Neo Ivy Capital Management acquired a new position in shares of Omnicell during the third quarter valued at approximately $78,000. Fifth Third Bancorp raised its holdings in Omnicell by 143.2% during the third quarter. Fifth Third Bancorp now owns 2,230 shares of the company’s stock worth $100,000 after purchasing an additional 1,313 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in Omnicell by 110.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,392 shares of the company’s stock worth $153,000 after purchasing an additional 1,777 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $30.12 on Friday. The stock’s fifty day simple moving average is $28.06 and its 200 day simple moving average is $31.40. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -65.48, a PEG ratio of 136.94 and a beta of 0.77. The company has a quick ratio of 2.13, a current ratio of 2.38 and a debt-to-equity ratio of 0.48. Omnicell, Inc. has a 52-week low of $25.69 and a 52-week high of $77.14.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. The firm had revenue of $258.85 million for the quarter, compared to analysts’ expectations of $256.00 million. As a group, sell-side analysts forecast that Omnicell, Inc. will post 0.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on OMCL. Benchmark reiterated a “buy” rating and set a $38.00 price target on shares of Omnicell in a research report on Tuesday, April 30th. Wells Fargo & Company lowered their target price on Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $42.20.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.